Chemotherapy-Related Differences in Cognitive Functioning and Their Biological Predictors in Patients with Multiple Myeloma

• Main Authors: Magdalena Bury-Kamińska, Aneta Szudy-Szczyrek, Aleksandra Nowaczyńska, Olga Jankowska-Łęcka, Marek Hus, Klaudia Kot
• Format: Article
• Language: English
• Published: MDPI AG 2021-09-01
• Series: Brain Sciences
• Subjects: cancer-related cognitive dysfunctions; cytokines; hematooncology
• Online Access: https://www.mdpi.com/2076-3425/11/9/1166

The paper presents a study on the changes in cognitive functioning in patients undergoing chemotherapy with diagnosed multiple myeloma (MM). The aim of the study was to answer the following two main research questions: Does the treatment stage differentiate the functioning of cognitive processes in patients with diagnosed MM and to what extent? Is it possible to treat biological factors (TNF-α, IL-6, IL-10, and BDNF) as predictors of patients’ cognitive functioning? The patients were examined twice, before the treatment and after 4–6 cycles of chemotherapy. Selected neuropsychological research methods as well as experimental and clinical trials were employed to diagnose the patients’ general cognitive state, attention, memory, and executive functions. The level of biological factors was assessed with the ELISA test. The results show that the patients’ cognitive functioning was worse before the treatment than during the cytostatic therapy. It was also possible to predict the cognitive state of patients suffering from multiple myeloma based on a selected biological parameter (neurotrophin BDNF).